口咽癌生物学适应性放疗(BARitOne):R-IDEAL 2a-2b期技术优化、可行性与安全性研究方案
BARitOne为单中心R-IDEAL 2a-2b期研究,纳入预后不良的3-4b期口咽鳞癌接受单纯根治性放疗者,全部起始65Gy/30次,在第1和第10次行DW-MRI根据ADC变化分层为应答者与无应答者,无应答者第16-30次对GTV加量至总量73Gy/30次,主要目的是评估完成DW-MRI引导应答适应性放疗的参与者比例。
要点
- 预后不良3-4b期口咽鳞癌起始标准放疗65Gy/30次,第1、10次DW-MRI分层。
- 无应答者第16-30次对GTV加量40.5Gy/15次,GTV总量73Gy/30次。
- 主要目的是评估完成DW-MRI引导应答适应性放疗的参与者比例。
核心结论
- DW-MRI引导的生物学适应性放疗可用于识别预测标准放疗失败的OPSCC并实施个体化加量。
- BARitOne旨在优化并评估该应答适应性工作流程的可行性。
研究设计与样本
- 单中心R-IDEAL 2a和2b期研究,纳入接受单纯根治性放疗的预后不良3-4b期OPSCC患者。
- 所有参与者起始标准放疗65Gy/30次,第1和第10次行DW-MRI评估原发灶与淋巴结ADC变化并分层为应答者和无应答者。
主要发现
- 无应答者第16至30次对GTV加量40.5Gy/15次,GTV总剂量73Gy/30次;应答者继续标准治疗。
- 主要目的是评估完成DW-MRI引导应答适应性放疗的参与者比例。
关键数值与推荐
- 标准放疗剂量为65Gy/30次。
- 无应答者GTV加量为40.5Gy/15次,GTV总剂量73Gy/30次。
- DW-MRI于第1次和第10次分次进行,依据原发灶和淋巴结ADC变化分层。
临床怎么用
- 对预后不良OPSCC在放疗早期用DW-MRI识别无应答者并个体化加量,避免对全人群统一强化治疗。
- 实施前需优化影像引导应答适应性放疗工作流程,并避免根治性治疗中断。
局限性
- 为单中心研究方案,主要评估可行性与技术优化,尚不能提供疗效结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of head and neck squamous cell cancer (HNSCC), including HPV-positive and negative oropharyngeal squamous cell cancer (OPSCC) is rising. HPV-negative and some HPV-positive OPSCC has poor outcomes. Attempts to uniformly intensify treatment in poor-prognosis HNSCC populations have been unsuccessful. Diffusion-weighted MRI (DW-MRI) has been used during radiotherapy to identify OPSCC which will fail standard radiotherapy. Biologically-adaptive, DW-MRI guided radiotherapy may allow dose-escalated radiotherapy to be delivered to populations predicted to fail standard treatment, i.e. those really in need of treatment intensification. While individual components of response-adapted workflow are not novel, their combination is significantly different. The BARitOne (Biologically Adaptive Radiotherapy for Oropharyngeal Cancer) study aims to allow optimisation and evaluate feasibility of this approach. METHODS: BARitOne is a single-centre R-IDEAL stage 2a and b study of patients with poor-prognosis stage 3-4b OPSCC undergoing single-modality radical radiotherapy. All participants commence standard radiotherapy, 65Gy in 30 fractions. DW-MRI at fraction 1 and 10 assess change in apparent diffusion coefficient (ADC) in primary and nodal disease and stratify tumours into 'responders' and 'non-responders'. Non-responders receive dose-escalation (40.5Gy in 15 fractions) to the gross tumour volume (GTV) for fractions 16 to 30;total dose 73Gy in 30 fractions to GTV. Responders continue standard treatment. The primary aim is to evaluate the proportion of participants that complete DW-MRI guided response-adapted radiotherapy. DISCUSSION: Identifying non-responding tumours is an essential step towards individualising intensified radiotherapy for high-risk disease. The additional burden that image-guided, response-adaptive radiotherapy brings, along with the imperative to avoid gaps in radical treatment means workflow needs development and optimised prior to large-scale implementation and comparison to the current standard. BARitOne offers this, with learning also transferrable to other tumour types. While uniform treatment intensification for entire poor-prognostic HNSCC populations has failed to improve survival outcomes, this individualised and biomarker-guided approach to intensification offers an alternative strategy. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number ISRCTN45653542.
引用
- Anderson S, Douglas MC, Valentine R, et al. Biologically adaptive radiotherapy for oropharyngeal Cancer (BARitOne): An R-IDEAL stage 2a-2b technical optimisation, feasibility, and safety study - Study protocol. Clin Transl Radiat Oncol. 2026. PMID: 42568775. doi:10.1016/j.ctro.2026.101245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。